HAMILTON, Bermuda, Sept. 6, 2016 /PRNewswire/ -- Axovant
Sciences Ltd. (NYSE: AXON), a leading clinical-stage
biopharmaceutical company focused on the treatment of dementia,
today announced that the company will be presenting at the Morgan
Stanley Global Healthcare Conference on September 13 at 5:15 p.m.
EDT.
A simultaneous webcast can be accessed by visiting the Investors
section of www.axovant.com and selecting Events and
Presentations. A replay will be available for 30 days following the
conference.
About Axovant
Axovant Sciences Ltd. is a leading
clinical-stage biopharmaceutical company focused on acquiring,
developing and commercializing novel therapeutics for the treatment
of dementia. Axovant intends to develop a pipeline of product
candidates to comprehensively address the cognitive, functional and
behavioral aspects of dementia and related neurological disorders.
Our vision is to become the leading company focused on the
treatment of dementia by addressing all forms and aspects of this
condition.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-300323102.html
SOURCE Axovant Sciences Ltd.